Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) reported on Friday the availability of the generic version of Estrace Cream (estradiol vaginal cream, USP, 0.01%).
US Food and Drug Administration final approval for the generic Estrace Cream was awarded to the company's manufacturing and development partner, Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) in late January.
For the 12 months ending January 2018, Estrace Cream had annual US sales of approximately USD469m, according to IQVIA.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer, concluded the company.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream